GSK (NYSE:GSK) Issues FY 2026 Earnings Guidance

GSK (NYSE:GSK) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 4.900-5.000 for the period, compared to the consensus earnings per share estimate of 4.870. The company issued revenue guidance of $44.8 billion-$45.6 billion, compared to the consensus revenue estimate of $44.4 billion. GSK also updated its FY 2031 guidance to EPS.

GSK Trading Up 6.7%

Shares of NYSE GSK traded up $3.60 on Wednesday, reaching $56.94. 3,943,636 shares of the company traded hands, compared to its average volume of 5,101,853. The company has a 50 day moving average of $49.24 and a 200 day moving average of $44.54. The company has a current ratio of 0.84, a quick ratio of 0.55 and a debt-to-equity ratio of 0.95. GSK has a fifty-two week low of $32.38 and a fifty-two week high of $57.53. The stock has a market capitalization of $116.06 billion, a PE ratio of 16.08, a P/E/G ratio of 1.54 and a beta of 0.46.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Citigroup started coverage on GSK in a research note on Tuesday, January 27th. They set a “neutral” rating for the company. Morgan Stanley restated an “underweight” rating on shares of GSK in a research note on Wednesday, January 14th. Barclays downgraded GSK from an “equal weight” rating to an “underweight” rating in a report on Tuesday, January 6th. Bank of America upgraded GSK from an “underperform” rating to a “neutral” rating in a research note on Tuesday, November 25th. Finally, Cfra set a $53.00 price target on GSK in a research report on Thursday, October 30th. Two analysts have rated the stock with a Buy rating, five have given a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat, GSK has an average rating of “Reduce” and a consensus target price of $44.13.

Insider Transactions at GSK

In other news, major shareholder Plc Gsk purchased 1,470,000 shares of the stock in a transaction on Thursday, December 11th. The shares were acquired at an average price of $19.00 per share, with a total value of $27,930,000.00. Following the completion of the acquisition, the insider directly owned 18,245,691 shares of the company’s stock, valued at $346,668,129. This trade represents a 8.76% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 10.00% of the company’s stock.

Key Stories Impacting GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Q4 beat — GSK reported Q4 EPS above consensus and revenue well ahead of estimates, driven by strong demand in Specialty Medicines (HIV, oncology, immunology). This underpins the share move and improves near-term earnings visibility. Read More.
• Positive Sentiment: FY-2026 guidance slightly above Street — GSK set EPS guidance of $4.90–$5.00 and revenue guidance of $44.8B–$45.6B, a touch above consensus, which supports the stock given higher 2026 revenue/earnings expectations. Read More.
• Positive Sentiment: Specialty medicines and capital returns — Management highlighted double-digit growth in specialty franchises and reaffirmed medium-term targets while raising the dividend, supporting cash-generation and investor returns. Read More.
• Neutral Sentiment: Management set a deliberately modest 2026 bar — analysts note the company beat but chose cautious 2026 guidance; this could be prudent conservatism or an opportunity for upside if execution exceeds guide. Read More.
• Neutral Sentiment: New CEO signals M&A and faster development — leadership is pursuing bolt-on deals (~$2–4B) and efficiency in R&D; potential upside if acquisitions accelerate pipeline, but execution/timing is uncertain. Read More.
• Negative Sentiment: Guidance flags slower 2026 sales growth — company warned of slower growth next year as some patent expiries/competitive pressures loom, which could cap revenue momentum near term. Read More.
• Negative Sentiment: R&D setbacks and portfolio pullbacks — GSK returned rights to Wave’s RNA-editing program after disappointing early data and is executing R&D reorganization (job cuts), which weakens near-term pipeline optionality. Read More.
• Negative Sentiment: Workforce reductions tied to R&D overhaul — cuts in the UK and US are intended to streamline R&D but may signal near-term disruption and execution risk. Read More.

Institutional Trading of GSK

Several institutional investors and hedge funds have recently made changes to their positions in the company. Triumph Capital Management purchased a new position in GSK in the third quarter valued at about $40,000. SkyView Investment Advisors LLC bought a new position in GSK in the 2nd quarter worth about $303,000. Gabelli Funds LLC boosted its position in shares of GSK by 17.8% during the second quarter. Gabelli Funds LLC now owns 7,960 shares of the pharmaceutical company’s stock worth $306,000 after buying an additional 1,200 shares during the period. Brighton Jones LLC acquired a new stake in GSK in the 4th quarter valued at approximately $528,000. Finally, IHT Wealth Management LLC boosted its position in GSK by 12.1% during the 2nd quarter. IHT Wealth Management LLC now owns 14,736 shares of the pharmaceutical company’s stock worth $566,000 after acquiring an additional 1,589 shares during the period. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.